We have determined the molecular basis for hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency in a patient, J.H., with Lesch-Nyhan syndrome. Radioimmunoassay of lysates of erythrocytes or cultured B-lymphoblasts showed that this patient had no detectable HPRT enzyme activity or HPRT protein.
INTRODUCTION
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) is a cytoplasmic enzyme involved in the salvage of purine bases. HPRT catalyzes the formation of IMP and GMP from hypoxanthine and guanine, respectively. Partial deficiency of this enzyme results in overproduction of uric acid leading to severe, precocious gout and nephrolithiasis (Kelley et al., 1967) . Virtually complete deficiency of HPRT causes Lesch-Nyhan syndrome consisting of hyperuricemia, hyperuricaciduria and devastating neurological dysfunction, the hallmarks of which are mental retardation, spasticity, choreoathetosis and compulsive self-mutilation (Lesch and Nyhan, 1964; Seegmiller et al., 1967) . The importance of the study of HPRT goes beyond these human diseases. Because of selection systems for both the HPRT' and HPRT-phenotypes, this protein and its gene have become important tools in genetic research (Szybalska and Szybalski, 1962; Rubin et al., 1971) .
Subjects with HPRT deficiency reveal a striking degree of phenotypic and genotypic variety (Yang et al., 1984; Wilson et al., 1986a; Gibbs and Caskey, 1987) . However, studies of the HPRT gene and mRNA from deficient subjects using Southern-and Northern-blot techniques are normal in most cases (Yang et al., 1984; Wilson et al., 1986a) . Thus, more detailed analysis of HPRT gene sequences is necessary to understand themolecular bases for enzymatic abnormalities.
Six mutant forms of HPRT from deficient subjects have been characterized previously at the molecular level. The amino acid substitutions in four mutant forms of HPRT were determined by amino acid sequencing of aberrant peptides derived from highly purified erythrocyte HPRT from deficient subjects (Wilson and Kelley, 1983a; Wilson et al., 1983b Wilson et al., , 1984 . This technique is limited to those HPRTdeficient subjects who express suflicient levels of HPRT protein for purification and amino acid sequence determination. Furthermore, this technique is time consuming and does not necessarily reveal the underlying mutation. More recently, we have exploited the observation that approximately 80 % of HPRT deficient subjects have sufficient amounts of HPRT-specific mRNA for cDNA cloning in order to define the mutations in two other HPRT variants (Davidson et al., 1988; Fujimori et al., 1988) .
Previously identified mutations in HPRT are widely scattered throughout the primary structure.
HPPTMidi,d, the mutant described in this study, is due to a single aa substitution located only two aa residues from a previously defined HPRT variant, HPRT,,, Arbor (Fujimori et al., 1988) . Both mutations fall in the putative PRPP binding domain of HPRT (Argos et al., 1983) . Additionally, the region in which these mutations are found is conserved among different species.
EXPERIMENTAL AND DISCUSSION

(a) Cell lines
A patient (J.H.) with Lesch-Nyhan syndrome had undetectable levels of HPRT activity in both erythrocytes and cultured B-lymphoblasts (< 0.1 mU/mg or < 0.7 y0 of control values) (Wilson et al., 1986a) . In addition, levels of HPRT protein were undetectable as measured by radioimmunoassay using polyclonal anti-human HPRT antiserum (< 1.5 ng CRM/mg or ~0.5% of control values) (Wilson et al., 1986a) . We have designated HPRT from this patient, as HPRTmidland.
HPRT,,, Arbor was originally described as an HPRT variant on the basis of enzymatic properties (Wilson et al., 1982a) . The mutation responsible for HPRT,,, Arbor has been defined (Fujimori et al., 1988) . In contrast to J.H., this patient had partial HPRT deficiency with 10% of control levels of enzyme activity, and 11 y0 of control values of CRM.
J.H. lymphoblasts were maintained in RPM1 medium with 5% fetal calf serum as described previously (Wilson et al., 1982a) .
(b) cDNA cloning and isolation of recombinants
Approximately 1 .O g (wet weight) of HPRThlidland B-lymphoblasts was used for extraction of total RNA using guanidium isothiocyanate (Chirgwin et al., 1979) followed by oligo(dT) chromatography to select for poly(A) + RNA (Aviv and Leder, 1972) . Ohgo(dT), primed cDNAs were synthesized, using 5 to 20 fig of poly(A)+ RNA according to established procedures (Okayama and Berg, 1982; Gubler and Hoffman, 1983) , and cloned in llgtl 1 (Young and Davis, 1983) .
The resultant cDNA library was screened with an MyI-TuqI fragment of normal human HPR TcDNA which represents 5'-noncoding and coding sequences (Brennand et al., 1983) . This 160-bp fragment was labeled with [a-3ZP]dCTP using hexadeoxynucleotide primers (Feinberg and Vogelstein, 1984) .
Two HPRT-specific cDNA clones, pHPJH1 and pHJH7, were isolated. Recombinant phages were purified from 20 ml of phage lysate using standard techniques (Maniatis et al., 1982) . The inserts were excised, separated from vector sequences and cloned Fig. 1 . Sequencing strategy for HPRTlvIidland cDNA clones pHPJH1 and pHPJH7. Both pHPJH7, which extends to nt -72 and pHPJH1, which extends to nt 12 were subcloned into the EcoRI site of M13mp18 or M13mp19 and sequenced with HPRT-specific oligodeoxynucleotide primers (arrows 1 through 5) and the Ml3 universal primer (unlabeled arrows). The nucleotide sequences of the HPRT-specific oligodeoxynucleotide primers are listed in Table I . The ATG start codon, TAA stop codon and poly(A) tail are indicated. The Hind111 (H)-Bali (B) fragment (255 bp) was subcloned into Hind111 + SnzaI-cut M13mp18 and M13mp19 for determination of 3'-noncoding sequences. These subclones were sequenced using the universal primer. The position of the mutation in pHPJH1 and pHPJH7 is indicated by the asterisk. Both clones were sequenced entirely in both directions. Open bar, 5' and 3' noncoding sequences; solid bar, coding sequences; stippled bar, poly(A) tail.
in M13mpl8 and M13mp19 for isolation of singlestranded phages (Messing, 1983) .
(c) Sequencing and recombinant analysis
Sequences of pHPJH1 and pHPJH7 were determined using the sequencing strategy described in Fig. 1 . Single-stranded Ml3 recombinant phages were sequenced with [c+~~S]~ATP (Biggin et al., 1983) using both the Ml3 universal primer and HPRT-specific primers. The sequences of the HPRT-specific primers are listed in Table I . Normal HPRT cDNA contains 590 nt of 3'-noncoding sequence, 654 nt of coding sequence, and from 110 to 170 nt of 5'-noncoding sequences (Jolly et al., 1982; 87 Pate1 et al., 1986) . Clone pHPJH7 consisted of 590 nt of 3'-noncoding sequence, 654 nt of coding sequence, and 77 nt of 5'-noncoding sequence. pHPJH1 lacks 17 nt of coding sequence. Both clones were sequenced in their entirety in both directions (sense and antisense strands).
Recombinant clones pHPJH1 and pHPJH7 differed from normal human HPRT cDNA at a single nucleotide (Fig. 2) : a T-to-A transversion at nt 389. This nucleotide substitution predicts a valine-toaspartic acid substitution at aa 130 (Fig. 3) .
The mutation in HPRT~idland occurs in a region strongly conserved among human, rodent, and E. coli phosphoribosyltransferases (Table II) . This was also the case in another HPRT variant with Lesch-Nyhan syndrome, HPRTFlint (Davidson et al., 1988) . Such regions are probably important for maintenance of normal catalytic and kinetic properties as well as structural integrity. The effect of the valine-to-aspartic acid change in HPRTMidland and the resultant disruption of this conserved sequence may induce secondary and/or tertiary structural changes which render the protein more unstable, accounting for the lack of detectable activity and protein in this mutant.,
The strongly conserved aa 129 through 137 have been implicated as part of the PRPP-binding domain (Argos et al., 1983) . However, any catalytic consequence of the mutation in HPRTMidland cannot be determined because of insufficient residual protein and activity. HPRT,,, Ar,,or has an elevated K, for PRPP probably due to the isoleucine to methionine change at 132. As in HPRTMilidland, the diminished amount of CRM in HPRT,,, Arbor may result from disruption of secondary or tertiary structure leading to enhanced proteolysis. Single-stranded phages intoning these sequences were sequenced using the ~deox~~cleotide chain termination method according to Biggin (1983) using JSPRT-specific primer 2 (Table I) . One fourth of each sequencing reaction mix was electrophoresed on a 6% polyacrylamide gel containing 8 M urea at constant power (60 W). The gels were then transferred to Whatman paper, dried under vacuum, autoradiographed for 2 to 8 11, and developed. The sequence is shown between the panels with T (normal) transverted to an A (HPRTMidland). GlnPRT (Argos et al., 1983) . b XGPRT, xanthine-guanine phosphoribosyltransferase; APRT, adenine phosphoribosyltransferase; OPRT, orotate phosphoribosyltransferase; GlnPRT, glutamine phosphoribosylp~ophosphate amidotransferase. c Residue numbers are based on the amino acid sequence of human HPRT (Wilson et al., 1982b) . d A, Wilson et al. (1982b); B, Fujimori et al. (1988) ; C,D, Konecki et al. (1982) ; E, Pratt and Subramani (1983) ; F, Wilson et al. (1986b) ; G, Dush et al. (1985) ; H, Hershey and Taylor (1986); I, Poulsen et al. (1983) ; J, Tso et al. (1983) . a Normal sequence for the region from aa 129-137. 
(d) Secondary structure predictions
A computer-assisted analysis of predicted secondary structure perturbations caused by the amino 89 acid substitutions in HPRThlidland was performed (Chou and Fasman, 1978) . Hydrophilicity moments were also calculated and overlaid on the secondary structure plots (Hopp and Woods, 1981) . The Sequence Analysis Software Package (Genetics Computer Group) for nucleic acid and protein structure analysis was used for calculation and plotting of predicted structures (Wolf et al., 1988) . This software is available through the University of Wisconsin Biotechnology Center, Madison, WI 53705. Predicted secondary structures for normal HPRT and HPRTMidland are shown in Fig. 4 aspartic acid in HPRTlllidland. Aspartic acid has a strong propensity to disrupt P-sheet structure and to form /?-turn structure, especially in the context found in HPRTNIidland (Chou and Fasman, 1978) . The predicted result of this mutation on the secondary structure is the replacement of the first region of B-sheet structure by two additional /%.trns beginning at or near aa 126 (Fig. 4) .
(e) Conclusions
The genetic basis for enzyme deficiency in HPRTMidiand has been determined by cDNA cloning. A single nucleotide alteration was determined by sequencing two cDNA clones derived from a subject with Lesch-Nyhan syndrome. The mutation in
HPRTMidiand is near the point mutation identified in HPRT,,, Arbor 3 a variant with partial HPRT activity. The HPRThlidland mutation disrupts the putative PRPP binding domain which consists of a region of sequence of 9 aa strongly conserved among human, rodent and bacterial phosphoribosyltransferases. The structural alteration may impair protein stability leading to diminished amounts of CRM in cells derived from this subject. Altered secondary structure patterns are predicted for HPRTMidland, consistent with this hypothesis. The HPRTMidland mutation is 167 nt away from a previously defined mutant, HPRTFii,t.
